Results 161 to 170 of about 79,680 (194)

Levodopa Efficacy and GLP‐1 Receptor Agonists

Movement Disorders Clinical Practice, EarlyView.
Catherine Martinez, Christine Girges, Thomas Foltynie, Anne‐Marie Wills   +3 more
wiley   +1 more source

Safety and Efficacy of Glucagon‐Like Peptide‐1 Receptor Agonists Use in Elderly People With Obesity—A Meta‐Analysis

Obesity, EarlyView.
ABSTRACT Objective This meta‐analysis evaluates the safety and efficacy of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) for the treatment of older adults with obesity compared to younger individuals. Methods A systematic review was conducted following PRISMA guidelines (PROSPERO CRD420251074381).
Inês Rego de Figueiredo, Filipa Sofia Simas, Angela Ghiletchi, João Oliveira Torres, José Silva‐Nunes   +4 more
wiley   +1 more source

Are GLP-1 receptor agonists a 'magic bullet' for cancer? [PDF]

Nat Rev Cancer
Hebert JR, Murphy EA, Playdon MC, Makowski L, Ibele AR, Fairman CM, Hofseth LJ.   +6 more
europepmc   +1 more source

Incidental Resolution of Dopamine Agonist Induced Impulse Control Disorder with GLP‐1 Receptor Agonist

Movement Disorders Clinical Practice, EarlyView.
Hannah Kelly, Thomas Davis
wiley   +1 more source

Evaluating the Evolving Real‐World Adverse Events of GLP‐1RAs Using FDA Adverse Event Reporting System (FAERS)

Obesity, EarlyView.
Web portal for interrogating Adverse Events of GLP‐1 RA in diabetes vs weight control/obesity. ABSTRACT Objective This study aimed to assess the spectrum and frequency of adverse events (AEs) linked to glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) using the US FDA Adverse Event Reporting System (FAERS).
David Stone, Mary Playdon, Stephen D. Hursting, Aik Choon Tan   +3 more
wiley   +1 more source

Survival and Recurrence With GLP-1 Receptor Agonists in Breast Cancer.

JAMA Netw Open
Tatum KL, Dahman B, Stevenson A, Williford SE, Cassel JB, Zhao H, Shen J, McGuire KP, Diala O, Oladimeji R, Hundley WG, Fuemmeler BF.   +11 more
europepmc   +1 more source

GLP-1 Agonists in Adolescent Obesity: A Narrative Review of Single, Dual, and Triple Agonists. [PDF]

Diabetes Metab Syndr Obes
Abid M, Sheikh KS, Ahmad MS, Jiang H.
europepmc   +1 more source

Responses to GLP‐1RA in White and Black Adults With Obesity: Insights From Generalized Additive Mixed Models of EHR Data

Obesity, EarlyView.
ABSTRACT Objective This study examined racial differences in weight loss and clinical response to glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) therapy among adults with obesity using real‐world data. Methods We retrospectively analyzed our institution's Research Data Warehouse (RDW) containing deidentified data from electronic health records ...
Jordan H. Mallette, Joshua S. Speed, Seth T. Lirette, Daniel Moore, John S. Clemmer   +4 more
wiley   +1 more source

Gastrointestinal Adverse Effects of GLP-1 and Dual GLP-1/GIP Receptor Agonists: A Comprehensive Update in Diabetic and Obese Populations. [PDF]

Diabetes Metab Syndr Obes
Yılmaz N, Bastemir M.
europepmc   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonist‐Based Agents and Body Composition: Filling More Gaps

Obesity, EarlyView.
ABSTRACT The last 2 decades have seen historic advances in the treatment of obesity. We are entering an era of defining obesity not by weight‐based outcomes but by changes in body composition. Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are forming the platform for obesity treatments based on their high level of efficacy. Body composition can
Robert L. Dubin, Tierra N. Sanders, Hunter M. Schwab, Steven B. Heymsfield, Frank L. Greenway   +4 more
wiley   +1 more source